Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi Chai

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Epidemiology and Psychiatric Sciences|March 3, 2024
Incidence of mental health diagnoses during the COVID-19 pandemic: a multinational network studyYi Chai, Kenneth K C Man, Hao Luo, et al.
Diabetes Care|June 4, 2025
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort StudyDaniel R Morales, Fan Bu, Benjamin Viernes, et al.
American Journal of Hematology|June 23, 2021
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasoneLarysa Sanchez, Xavier Leleu, Jennifer L Beaumont, et al.
American Journal of Hematology|March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaHolger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
American Journal of Hematology|June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic riskShambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
Open Research Europe|August 14, 2024
Science development study for the Atacama Large Aperture Submillimeter Telescope (AtLAST): Solar and stellar observationsSven Wedemeyer, Miroslav Barta, Roman Brajša, et al.
Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Journal of Hematology & Oncology|April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaMaria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
Cancer Research|October 30, 2024
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple MyelomaPraneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Epidemiology and Psychiatric Sciences|March 3, 2024
Incidence of mental health diagnoses during the COVID-19 pandemic: a multinational network studyYi Chai, Kenneth K C Man, Hao Luo, et al.
Diabetes Care|June 4, 2025
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort StudyDaniel R Morales, Fan Bu, Benjamin Viernes, et al.
American Journal of Hematology|June 23, 2021
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasoneLarysa Sanchez, Xavier Leleu, Jennifer L Beaumont, et al.
American Journal of Hematology|March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaHolger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
American Journal of Hematology|June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic riskShambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
Open Research Europe|August 14, 2024
Science development study for the Atacama Large Aperture Submillimeter Telescope (AtLAST): Solar and stellar observationsSven Wedemeyer, Miroslav Barta, Roman Brajša, et al.
Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Journal of Hematology & Oncology|April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaMaria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
Cancer Research|October 30, 2024
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple MyelomaPraneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
Pageof 19